{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:34:03Z","timestamp":1784212443209,"version":"3.55.0"},"reference-count":44,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,11,10]]},"abstract":"<jats:p>Background: Whether brain-derived neurotrophic factor (BDNF) Met carriage impacts the risk or progression of Alzheimer\u2019s disease (AD) is unknown. Objective: To evaluate the interaction of BDNF Met and APOE4 carriage on cerebral metabolic rate for glucose (CMRgl), amyloid burden, hippocampus volume, and cognitive decline among cognitively unimpaired (CU) adults enrolled in the Arizona APOE cohort study. Methods: 114 CU adults (mean age 56.85 years, 38% male) with longitudinal FDG PET, magnetic resonance imaging, and cognitive measures were BDNF and APOE genotyped. A subgroup of 58 individuals also had Pittsburgh B (PiB) PET imaging. We examined baseline CMRgl, PiB PET amyloid burden, CMRgl, and hippocampus volume change over time, and rate of change in cognition over an average of 15 years. Results: Among APOE4 carriers, BDNF Met carriers had significantly increased amyloid deposition and accelerated CMRgl decline in regions typically affected by AD, but without accompanying acceleration of cognitive decline or hippocampal volume changes and with higher baseline frontal CMRgl and slower frontal decline relative to the Val\/Val group. The BDNF effects were not found among APOE4 non-carriers. Conclusion: Our preliminary studies suggest that there is a weak interaction between BDNF Met and APOE4 on amyloid-\u03b2 plaque burden and longitudinal PET measurements of AD-related CMRgl decline in cognitively unimpaired late-middle-aged and older adults, but with no apparent effect upon rate of cognitive decline. We suggest that cognitive effects of BDNF variants may be mitigated by compensatory increases in frontal brain activity\u2014findings that would need to be confirmed in larger studies.<\/jats:p>","DOI":"10.3233\/jad-200132","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T13:14:53Z","timestamp":1601990093000},"page":"721-734","source":"Crossref","is-referenced-by-count":17,"title":["Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer\u2019s Disease and Cognitive Decline"],"prefix":"10.1177","volume":"78","author":[{"given":"Cynthia M.","family":"Stonnington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie N.","family":"Velgos","sequence":"additional","affiliation":[{"name":"Mayo Clinic Graduate School of Biomedical Sciences, Clinical and Translational Science Track, Scottsdale, AZ, USA"},{"name":"Translational neuroscience and Aging Laboratory, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Chen","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameena","family":"Syed","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ, USA"},{"name":"Midwestern University, Glendale, AZ, USA"},{"name":"Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Huentelman","sequence":"additional","affiliation":[{"name":"The Translational Genomics Research Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Thiyyagura","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Lee","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Richholt","sequence":"additional","affiliation":[{"name":"The Translational Genomics Research Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Caselli","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dona E.C.","family":"Locke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Tsinghua University, Haidian Qu, Beijing Shi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, AZ, USA"},{"name":"The Translational Genomics Research Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Chen","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200132_ref1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200132_ref2","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200132_ref3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.21696","article-title":"Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age","volume":"65","author":"Kok","year":"2009","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200132_ref4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMoa0809437","article-title":"Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect","volume":"361","author":"Caselli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-200132_ref5","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1212\/WNL.0000000000000431","article-title":"Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease","volume":"82","author":"Mormino","year":"2014","journal-title":"Neurology"},{"key":"10.3233\/JAD-200132_ref6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-016-0231-9","article-title":"Peripheral apoE isoform levels in cognitively normal APOE epsilon3\/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism","volume":"9","author":"Nielsen","year":"2017","journal-title":"Res Ther"},{"key":"10.3233\/JAD-200132_ref7","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1073\/pnas.061509598","article-title":"Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer\u2019s disease","volume":"98","author":"Reiman","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200132_ref8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJM199603213341202","article-title":"Preclinical evidence of Alzheimer\u2019s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E","volume":"334","author":"Reiman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-200132_ref9","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1073\/pnas.0500579102","article-title":"Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism","volume":"102","author":"Reiman","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200132_ref10","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1073\/pnas.090106797","article-title":"Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer\u2019s disease","volume":"97","author":"Small","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200132_ref11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jama.1995.03520360056039","article-title":"Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease","volume":"273","author":"Small","year":"1995","journal-title":"JAMA"},{"key":"10.3233\/JAD-200132_ref12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archneurol.2009.913","article-title":"APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging","volume":"67","author":"Thambisetty","year":"2010","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200132_ref13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.410440226","article-title":"Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer\u2019s disease","volume":"44","author":"Reiman","year":"1998","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200132_ref14","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1523\/JNEUROSCI.0348-04.2004","article-title":"Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons","volume":"24","author":"Chen","year":"2004","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200132_ref15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","article-title":"The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function","volume":"112","author":"Egan","year":"2003","journal-title":"Cell"},{"key":"10.3233\/JAD-200132_ref16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1749-6632.2010.05722.x","article-title":"Variant brain-derived neurotrophic factor Val66Met endophenotypes: Implications for posttraumatic stress disorder","volume":"1208","author":"Frielingsdorf","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-200132_ref17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuroscience.2009.12.022","article-title":"Paradoxical association of the brain-derived-neurotrophic-factor val66met genotype with response inhibition","volume":"166","author":"Beste","year":"2010","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-200132_ref18","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/hmg\/ddm189","article-title":"Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor","volume":"16","author":"Zivadinov","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-200132_ref19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/ard.2006.051623","article-title":"The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus","volume":"65","author":"Oroszi","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.3233\/JAD-200132_ref20","doi-asserted-by":"crossref","first-page":"e88733","DOI":"10.1371\/journal.pone.0088733","article-title":"Preservation of general intelligence following traumatic brain injury: Contributions of the Met66 brain-derived neurotrophic factor","volume":"9","author":"Barbey","year":"2014","journal-title":"One"},{"key":"10.3233\/JAD-200132_ref21","first-page":"379","article-title":"Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimer\u2019s disease","volume":"367","author":"Nacmias","year":"2004","journal-title":"Lett"},{"key":"10.3233\/JAD-200132_ref22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00702-010-0539-8","article-title":"Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults","volume":"118","author":"Richter-Schmidinger","year":"2011","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JAD-200132_ref23","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1212\/WNL.0000000000003980","article-title":"BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer\u2019s Prevention","volume":"88","author":"Boots","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-200132_ref24","first-page":"165","article-title":"Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer\u2019s disease","volume":"39","author":"Gomar","year":"2016","journal-title":"Aging"},{"key":"10.3233\/JAD-200132_ref25","first-page":"2457","article-title":"BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer\u2019s disease","volume":"34","author":"Lim","year":"2013","journal-title":"Aging"},{"key":"10.3233\/JAD-200132_ref26","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/mp.2014.123","article-title":"APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer\u2019s disease","volume":"20","author":"Lim","year":"2015","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-200132_ref27","first-page":"512","article-title":"Polymorphism of brain derived neurotrophic factor influences beta amyloid load in cognitively intact apolipoprotein E epsilon4 carriers","volume":"2","author":"Adamczuk","year":"2013","journal-title":"Clin"},{"key":"10.3233\/JAD-200132_ref28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0b013e3182167147","article-title":"Longitudinal modeling of frontal cognition in APOE epsilon4 homozygotes, heterozygotes, and noncarriers","volume":"76","author":"Caselli","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-200132_ref29","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/archneur.64.9.1306","article-title":"Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment","volume":"64","author":"Caselli","year":"2007","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200132_ref30","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1212\/01.WNL.0000129533.26544.BF","article-title":"Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele","volume":"62","author":"Caselli","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-200132_ref31","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.neuroimage.2010.09.066","article-title":"Association between GAB2 haplotype and higher glucose metabolism in Alzheimer\u2019s disease-affected brain regions in cognitively normal APOEepsilon4 carriers","volume":"54","author":"Liang","year":"2011","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-200132_ref32","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa1900757","article-title":"Tau positron-emission tomography in former National Football League players","volume":"380","author":"Stern","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-200132_ref33","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.neuroimage.2008.12.072","article-title":"Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","volume":"45","author":"Langbaum","year":"2009","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-200132_ref34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","article-title":"Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain","volume":"33","author":"Fischl","year":"2002","journal-title":"Neuron"},{"key":"10.3233\/JAD-200132_ref35","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.neuroimage.2004.07.016","article-title":"Sequence-independent segmentation of magnetic resonance images","volume":"23 Suppl 1","author":"Fischl","year":"2004","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-200132_ref36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0000000000000467","article-title":"Association of hypometabolism and amyloid levels in aging, normal subjects","volume":"82","author":"Lowe","year":"2014","journal-title":"Neurology"},{"key":"10.3233\/JAD-200132_ref37","first-page":"32","article-title":"Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum","volume":"46","author":"Knopman","year":"2016","journal-title":"Aging"},{"key":"10.3233\/JAD-200132_ref38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3233\/JAD-180971","article-title":"The influence of BDNF Val66Met polymorphism on cognition, cerebrospinal fluid, and neuroimaging markers in non-demented elderly","volume":"68","author":"Xia","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200132_ref39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JAD-190464","article-title":"Impact of APOE and BDNF Val66Met gene polymorphisms on cognitive functions in patients with amnestic mild cognitive impairment","volume":"73","author":"Cechova","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200132_ref40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/WNR.0b013e32833ccaf4","article-title":"Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer\u2019s disease","volume":"21","author":"Xu","year":"2010","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-200132_ref41","first-page":"377","article-title":"The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: An imaging genetic study","volume":"207","author":"Cerasa","year":"2010","journal-title":"Brain Res"},{"key":"10.3233\/JAD-200132_ref42","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3389\/fpsyg.2015.01212","article-title":"The brain-derived neurotrophic factor (BDNF) val66met polymorphism differentially affects performance on subscales of the Wechsler Memory Scale - Third Edition (WMS-III)","volume":"6","author":"Lamb","year":"2015","journal-title":"Front Psychol"},{"key":"10.3233\/JAD-200132_ref43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1212\/WNL.0b013e318211c3ae","article-title":"Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes","volume":"76","author":"Caselli","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-200132_ref44","unstructured":"Hosmer DW Jr. , Lemeshow S (1989) Applied logistic regression. Wiley, New York."}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:06Z","timestamp":1777370946000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":44,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-200132","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}